BillionToOne: Molecular Diagnostics Stock With Strong Quality And GARP Credentials (BLLN)
· seekingalpha.com
BillionToOne (BLLN) stock analysis: QCT-driven diagnostics, 70% GMS and 38% growth vs peers. Read here for a detailed investment analysis.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions...